Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group

Carla Damaschin; Helen Goergen; Stefanie Kreissl; Annette Plütschow; Frank Breywisch; Stephan Mathas; Julia Meissner; Martin Sökler; Max S Topp; Vladan Vucinic; Andreas Zimmermann; Bastian von Tresckow; Michael Fuchs; Andreas Engert; Peter Borchmann; Dennis A Eichenauer

doi:10.1038/s41375-021-01386-z

Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group

Leukemia. 2022 Feb;36(2):580-582. doi: 10.1038/s41375-021-01386-z. Epub 2021 Aug 18.

Authors

Carla Damaschin^{1

2}, Helen Goergen^{1

2}, Stefanie Kreissl^{1

2}, Annette Plütschow^{1

2}, Frank Breywisch³, Stephan Mathas⁴, Julia Meissner⁵, Martin Sökler⁶, Max S Topp⁷, Vladan Vucinic⁸, Andreas Zimmermann⁹, Bastian von Tresckow^{2

10}, Michael Fuchs^{1

2}, Andreas Engert^{1

2}, Peter Borchmann^{1

2}, Dennis A Eichenauer^{11

12}

Affiliations

¹ First Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, Cologne, Germany.
² German Hodgkin Study Group (GHSG), University Hospital Cologne, Cologne, Germany.
³ Department of Hematology, Oncology and Palliative Care, Klinikum Ernst von Bergmann, Potsdam, Germany.
⁴ Department of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, Max-Delbrück-Center for Molecular Medicine, Berlin, and Experimental and Clinical Research Center (ECRC), Berlin, Germany.
⁵ Fifth Department of Internal Medicine, University Hospital Heidelberg, Heidelberg, Germany.
⁶ Second Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany.
⁷ Second Department of Internal Medicine, University Hospital Würzburg, Würzburg, Germany.
⁸ Department of Hematology and Cell Therapy, Medical Oncology, Hemostaseology, University Hospital Leipzig, Leipzig, Germany.
⁹ Department of Internal Medicine III, University Hospital Munich, Munich, Germany.
¹⁰ Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
¹¹ First Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, Cologne, Germany. dennis.eichenauer@uk-koeln.de.
¹² German Hodgkin Study Group (GHSG), University Hospital Cologne, Cologne, Germany. dennis.eichenauer@uk-koeln.de.

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bleomycin / administration & dosage
Brentuximab Vedotin / administration & dosage
Clinical Trials, Phase II as Topic / statistics & numerical data*
Cyclophosphamide / administration & dosage
Etoposide / administration & dosage
Female
Follow-Up Studies
Hodgkin Disease / drug therapy*
Hodgkin Disease / pathology
Humans
Male
Middle Aged
Neoplasm Recurrence, Local / drug therapy*
Neoplasm Recurrence, Local / pathology
Neoplasms, Second Primary / drug therapy*
Neoplasms, Second Primary / pathology
Prognosis
Randomized Controlled Trials as Topic / statistics & numerical data*
Survival Rate
Vincristine / administration & dosage
Young Adult

Substances

Bleomycin
Vincristine
Etoposide
Brentuximab Vedotin
Cyclophosphamide